Our Technology
AmacaThera has developed a novel hydrogel to deliver localized therapeutics. Our technology is unique. We've demonstrated GMP manufacturability and are conducting human safety testing
Injectable Hydrogel Solution
(AmacaGel)
Injectable hydrogel transitions from liquid to gel at body temperature, ensuring drugs stay at the target site for enhanced therapeutic effect
Platform provides customizable drug release profiles burst, sustained, or combined to meet various clinical needs from post-surgical pain to oncology
Based in Groundbreaking, Innovative Research
AmacaThera was spun out of The Shoichet Lab as a commercial company in 2016, with support from Toronto's early-stage biotechnology sector.
Versatility and Scalability
developed through innovative research:
AmacaGel can deliver small molecules, growth factors, antibodies, stem cells, and enzymes
straightforward "mix and fill" process reduces production costs and supports global scalability
Why choose AmacaThera's hydrogel platform?
Targets hard-to-reach sites, including incision areas, brain, and eye tissue, for conditions ranging from post-surgical pain to oncology
Accommodates a broad range of therapeutic modalities, from small molecules and biologics to stem cells and enzymes
Shear-thinning hydrogel enables convenient dosing via pre-filled syringe, integrating smoothly into surgical workflows
Constructed from approved, well-tested materials to minimize risk and support clinical use
Clinically validated, with demonstrated safety and efficacy in both preclinical and phase 1 human trials
Flexible platform for controlled drug delivery to diverse anatomical locations, enhancing dosing and therapeutic outcomes
Strong intellectual property portfolio and readiness for GMP-scale manufacturing